8/16/2007

Australian biotech EvoGenix Ltd. said it has begun the second of three proposed projects with U.K.-based GlaxoSmithKline involving technologies used to develop antibodies for the market. The latest collaboration will attempt to "improve the properties of either an antibody or a protein to ... increase the effectiveness of drugs," EvoGenix CEO Dr. Merilyn Sleigh said.

Related Summaries